Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lyell Immunopharma (LYEL)
NASDAQ:LYEL
Holding LYEL?
Track your performance easily
LYEL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.85 - $3.26
Previous Close$0.95
Volume3.71M
Average Volume (3M)1.20M
Market Cap
$265.26M
Enterprise Value-$123.85M
Total Cash (Recent Filing)$440.55M
Total Debt (Recent Filing)$51.44M
Price to Earnings (P/E)―
Beta2.60
Next Earnings
Feb 26, 2025EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding279,220,614
10 Day Avg. Volume1,411,434
30 Day Avg. Volume1,202,736
Standard Deviation0.25
R-Squared0.00886
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.54
Price to Sales (P/S)4919.60
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.97K
Enterprise Value/Gross Profit-952.66
Enterprise Value/Ebitda0.70
Forecast
1Y Price Target
$1.00Price Target Upside9.54% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering2
Lyell Immunopharma News
PremiumCompany Announcements
Lyell Immunopharma Reports Q3 2024 Financial Results
PremiumPre-Earnings
Is LYEL a Buy, Before Earnings?
PremiumCompany Announcements
Lyell Immunopharma’s Strategic Moves and Leadership Expansion
PremiumCompany Announcements
Lyell Immunopharma Acquires ImmPACT Bio to Enhance PipelineBulls Say, Bears Say
Bulls Say
Financial StabilityLyell ended 3Q24 with $461M in cash, which management expects to provide an operational runway into 2027.
Innovative TherapiesOptimism is growing for next-gen LYL119’s improved therapeutic window.
Strategic AcquisitionsThe acquisition of ImmPACT Biosciences focuses Lyell Immunopharma on a promising CAR-T cell therapy for B-cell lymphomas.
Bears Say
Financial PerformanceEven with a promising product candidate, Lyell's high development costs and competitive landscape contribute to a Neutral rating.
Market CompetitionThe CD19-targeted CAR-T space is crowded, and the opportunity for another entrant like Lyell is limited.
Product Development IssuesDevelopment of several legacy pipeline programs, including LYL797 and LYL845, has been discontinued with no sufficient evidence of benefits from the second-generation ROR1 CAR-T.
---
Ownership Overview
17.75% Insiders
9.54% Mutual Funds
25.65% Other Institutional Investors
39.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LYEL FAQ
What was Lyell Immunopharma’s price range in the past 12 months?
Lyell Immunopharma lowest stock price was $0.85 and its highest was $3.25 in the past 12 months.
What is Lyell Immunopharma’s market cap?
Currently, no data Available
When is Lyell Immunopharma’s upcoming earnings report date?
Lyell Immunopharma’s upcoming earnings report date is Feb 26, 2025 which is in 92 days.
How were Lyell Immunopharma’s earnings last quarter?
Lyell Immunopharma released its earnings results on Nov 07, 2024. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.025.
Is Lyell Immunopharma overvalued?
According to Wall Street analysts Lyell Immunopharma’s price is currently Undervalued.
Does Lyell Immunopharma pay dividends?
Lyell Immunopharma does not currently pay dividends.
What is Lyell Immunopharma’s EPS estimate?
Lyell Immunopharma’s EPS estimate is -$0.19.
How many shares outstanding does Lyell Immunopharma have?
Lyell Immunopharma has 279,220,600 shares outstanding.
What happened to Lyell Immunopharma’s price movement after its last earnings report?
Lyell Immunopharma reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.195. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lyell Immunopharma?
Among the largest hedge funds holding Lyell Immunopharma’s share is EntryPoint Capital, LLC. It holds Lyell Immunopharma’s shares valued at 287K.
---
Lyell Immunopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$1.00 (9.54% Upside)
$1.00 (9.54% Upside)
Blogger Sentiment
Neutral
LYEL Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 187.3K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.08%
12-Months-Change
Fundamentals
Return on Equity
-33.22%
Trailing 12-Months
Asset Growth
-22.11%
Trailing 12-Months
Company Description
Lyell Immunopharma
Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors.
---
LYEL Stock 12 Month Forecast
Average Price Target
$1.00
▲(9.54% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Fate Therapeutics
―
Intellia Therapeutics
―
Best Analysts Covering LYEL
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-61.93%
reiterated a buy rating 7 months ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -61.93% per trade.
---